Parallax Volatility Advisers
RPRX icon

Parallax Volatility Advisers’s Royalty Pharma RPRX Stock Holding History

Parallax Volatility Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,000
Closed -$674K – 2274
2023
Q4 		$674K Buy
24,000
+21,500
+860% +$591K ﹤0.01% 1525
2023
Q3 		$67.8K Buy
+2,500
New +$74.3K ﹤0.01% 1983

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Parallax Volatility Advisers's RPRX Position: Q1 2026 in Review

Parallax Volatility Advisers sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 9,509 shares — an estimated $367K sold.

Parallax Volatility Advisers first reported a position in RPRX in Q2 2020 and held it in 3 quarters. The position peaked at $373K in Q2 2020. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Parallax Volatility Advisers reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
  • Parallax Volatility Advisers sold 9,509 Royalty Pharma shares in Q1 2026, an estimated $367K.
  • Parallax Volatility Advisers first reported a position in Royalty Pharma in Q2 2020 and held it in 3 quarters.
  • Parallax Volatility Advisers's Royalty Pharma position peaked at $373K in Q2 2020.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.